About
Warp Sciences is a US drug-development startup building a fully automated chemistry lab, training AI-guided robots to synthesize and test the many molecular variants pharma researchers generate after identifying a promising compound.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 4
Founders / team· 4
Funding history
- 2026-10-22New funding round$215M
Investors · Lightspeed, IVP, Premji Invest, Lux CapitalSource · bloomberg.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Warp Sciences
Warp Sciences is a US drug-development startup building a fully automated chemistry lab, training AI-guided robots to synthesize and test the many molecular variants pharma researchers generate after identifying a promising compound.
$215M · 2026-10
$215M
United States
BusinessLatest roundTotal raisedDate- Pathos AI
Uses artificial intelligence and robotic automation to accelerate the development of targeted therapies for solid tumors
Series D+ · $602M · 2026-10 · Valuation $3.0B
$602MValuation $3.0B - Terray Therapeutics
Combines AI with wet lab science to discover new small-molecule drugs
Undisclosed · $120M · 2024-10
$120M - Vivodyne
Robotic automation to produce human tissue for faster drug testing
Series A · $40M · 2025-05
$40M
China
BusinessLatest roundTotal raisedDate- Coherence Biotech Co. Ltd.
Lab automation: the Keystone™ benchtop all-in-one system combines culturing, intervention and microscopy imaging into uninterrupted multi-day cell/organoid experiments and uses AI vision to identify, count and track cells, generating structured experimental data for AI drug discovery
— - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M - HOURS
AI chemical synthesis route and process design platform plus automated experimentation, for pharma CROs/CMOs and chemical and new energy materials companies
Undisclosed · 2026-09
—
Europe
BusinessLatest roundTotal raisedDate- Rivercell
In-house automated wet lab generating large-scale single-cell perturbation data to train "AI virtual cell" models that predict human cell responses to drugs and genetic changes
Seed · 2026-10
— - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B - Causaly
AI platform that helps researchers accelerate drug development and testing
Series B · $60M · 2023-07
$60M
Other / unspecified
BusinessLatest roundTotal raisedDate- Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
— - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in United States
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.